Skyrizi and Pregnancy: Current Knowledge

The safety of Skyrizi during pregnancy is not well-established. According to Medical News Today, there is insufficient data to determine the risk of major birth defects, miscarriage, or adverse maternal outcomes associated with Skyrizi use during pregnancy. Animal studies have suggested potential risks to the fetus, but these findings do not necessarily apply to humans.

The FDA has not assigned a specific pregnancy category to Skyrizi, indicating that the available data is insufficient to make a definitive risk assessment. Healthcare providers are advised to weigh the benefits of controlling Crohn's disease against the potential risks of fetal exposure when considering Skyrizi for pregnant patients.

Clinical Insights and Recommendations

A review published in PMC emphasizes the importance of maintaining disease remission in pregnant women with Crohn's disease to improve both maternal and fetal outcomes. While Skyrizi is considered a treatment option, the lack of extensive human data necessitates careful consideration and consultation with healthcare providers.

The GLOW Pregnancy Registry is actively collecting data on the use of Skyrizi during pregnancy to better understand its safety profile. Patients using Skyrizi who become pregnant are encouraged to enroll in this registry to contribute to the growing body of knowledge.

Patient Experiences and Considerations

While there are anecdotal reports of women using Skyrizi during pregnancy, comprehensive data is limited. The Crohn's & Colitis Foundation notes that while older biologics have more established safety profiles, newer agents like Skyrizi require further study. Patients are advised to discuss their treatment options thoroughly with their healthcare providers, considering both the potential risks of medication and the risks of untreated disease.